Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder

Brigette Vaughan; Christopher J. Kratochvil

doi:10.1016/j.chc.2012.07.005

Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder

Brigette Vaughan, Christopher J. Kratochvil

Research output: Contribution to journal › Review article › peer-review

30 Scopus citations

Abstract

This article describes the practical use of available attention-deficit/hyperactivity disorder (ADHD) pharmacotherapies, their formulations and durations of action, and the extent of Food and Drug Administration approvals. It provides data on short-term and long-term safety of these medications, their use in ADHD with comorbid conditions, and strategies for formulating individualized, effective, and well-tolerated pharmacotherapy treatment plans. A clinical vignette focusing on a male child with ADHD is presented. Summaries are presented of ADHD pharmacotherapies and Food and Drug Administration approval status, atomoxetine and stimulant comparator trials, adverse effects and ADHD pharmacotherapy, and delivery system and duration of effect.

Original language	English (US)
Pages (from-to)	941-955
Number of pages	15
Journal	Child and Adolescent Psychiatric Clinics of North America
Volume	21
Issue number	4
DOIs	https://doi.org/10.1016/j.chc.2012.07.005
State	Published - Oct 2012

Keywords

ADHD
Amphetamine
Atomoxetine
Clonidine
Guanfacine
Methylphenidate
Pharmacotherapy

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Psychiatry and Mental health

Access to Document

10.1016/j.chc.2012.07.005

Cite this

@article{d82f2e9a15b14156a4d9791bb68ba9cb,

title = "Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder",

abstract = "This article describes the practical use of available attention-deficit/hyperactivity disorder (ADHD) pharmacotherapies, their formulations and durations of action, and the extent of Food and Drug Administration approvals. It provides data on short-term and long-term safety of these medications, their use in ADHD with comorbid conditions, and strategies for formulating individualized, effective, and well-tolerated pharmacotherapy treatment plans. A clinical vignette focusing on a male child with ADHD is presented. Summaries are presented of ADHD pharmacotherapies and Food and Drug Administration approval status, atomoxetine and stimulant comparator trials, adverse effects and ADHD pharmacotherapy, and delivery system and duration of effect.",

keywords = "ADHD, Amphetamine, Atomoxetine, Clonidine, Guanfacine, Methylphenidate, Pharmacotherapy",

author = "Brigette Vaughan and Kratochvil, {Christopher J.}",

note = "Funding Information: Disclosure: Brigette Vaughan: Nothing to report. Christopher J. Kratochvil, MD: This past year received grant support from Eli Lilly, Shire, and the National Institutes of Health; been a consultant for Seaside, Quintiles, Otsuka, Pfizer, and the Food and Drug Administration; and received royalties from Oxford Press. ",

year = "2012",

month = oct,

doi = "10.1016/j.chc.2012.07.005",

language = "English (US)",

volume = "21",

pages = "941--955",

journal = "Child and Adolescent Psychiatric Clinics of North America",

issn = "1056-4993",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder

AU - Vaughan, Brigette

AU - Kratochvil, Christopher J.

N1 - Funding Information: Disclosure: Brigette Vaughan: Nothing to report. Christopher J. Kratochvil, MD: This past year received grant support from Eli Lilly, Shire, and the National Institutes of Health; been a consultant for Seaside, Quintiles, Otsuka, Pfizer, and the Food and Drug Administration; and received royalties from Oxford Press.

PY - 2012/10

Y1 - 2012/10

N2 - This article describes the practical use of available attention-deficit/hyperactivity disorder (ADHD) pharmacotherapies, their formulations and durations of action, and the extent of Food and Drug Administration approvals. It provides data on short-term and long-term safety of these medications, their use in ADHD with comorbid conditions, and strategies for formulating individualized, effective, and well-tolerated pharmacotherapy treatment plans. A clinical vignette focusing on a male child with ADHD is presented. Summaries are presented of ADHD pharmacotherapies and Food and Drug Administration approval status, atomoxetine and stimulant comparator trials, adverse effects and ADHD pharmacotherapy, and delivery system and duration of effect.

AB - This article describes the practical use of available attention-deficit/hyperactivity disorder (ADHD) pharmacotherapies, their formulations and durations of action, and the extent of Food and Drug Administration approvals. It provides data on short-term and long-term safety of these medications, their use in ADHD with comorbid conditions, and strategies for formulating individualized, effective, and well-tolerated pharmacotherapy treatment plans. A clinical vignette focusing on a male child with ADHD is presented. Summaries are presented of ADHD pharmacotherapies and Food and Drug Administration approval status, atomoxetine and stimulant comparator trials, adverse effects and ADHD pharmacotherapy, and delivery system and duration of effect.

KW - ADHD

KW - Amphetamine

KW - Atomoxetine

KW - Clonidine

KW - Guanfacine

KW - Methylphenidate

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=84867081591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867081591&partnerID=8YFLogxK

U2 - 10.1016/j.chc.2012.07.005

DO - 10.1016/j.chc.2012.07.005

M3 - Review article

C2 - 23040908

AN - SCOPUS:84867081591

SN - 1056-4993

VL - 21

SP - 941

EP - 955

JO - Child and Adolescent Psychiatric Clinics of North America

JF - Child and Adolescent Psychiatric Clinics of North America

IS - 4

ER -

Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this